Nachrichten zur Johnson Service Group PLC Aktie

Johnson & Johnson Tops Q4 EPS Forecasts

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.…

Gutes Geschäft mit Krebsmedikamenten verleiht Johnson & Johnson Schub

NEW BRUNSWICK (dpa-AFX) - Der US-Konzern Johnson & Johnson (J&J) hat im vergangenen Jahr die Umsatzeinbußen bei einem seiner wichtigsten…

Johnson & Johnson: Dividenden-Aristokrat überzeugt

In einem dynamischen Gesundheitsmarkt, der von technologischen Innovationen und steigenden Gesundheitsausgaben geprägt ist, hat Johnson & Johnson seine Widerstandsfähigkeit und…

Johnson & Johnson: Dividenden-Aristokrat überzeugt

In einem dynamischen Gesundheitsmarkt, der von technologischen Innovationen und steigenden Gesundheitsausgaben geprägt ist, hat Johnson & Johnson seine Widerstandsfähigkeit und…

J&J beats quarterly sales and profit estimates on cancer drug sales

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter sales and…

Johnson & Johnson slides as soft sales guidance casts shadow

Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over…

Johnson & Johnson Aktie: Fokus auf makroökonomische Faktoren

London (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Barclays: Rating und Kursziel Barclays hat das Kursziel für die Aktie von Johnson & Johnson…

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care…

AIM movers: Trellus Health partners with Johnson & Johnson and Thruvision strategic review

Digital healthcare platform developer Trellus Health (LON: TRLS) has entered an agreement with Johnson & Johnson Health Care Systems Inc…

Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

…

Johnson & Johnson kündigt Übernahme von Intra-Cellular Therapies an.

WerbungFür rund 14,6 Milliarden US-Dollar kauft das Pharmaunternehmen den Arzneimittelhersteller.Wie am Montag bekannt gegeben wurde, wird das Pharmaunternehmen Johnson &…

Milliarden-Deal! Johnson & Johnson schluckt AKTIONÄR-Tipp Intra-Cellular – satte Prämie

Die diesjährige JPMorgan Healthcare Conference beginnt mit einem Paukenschlag: Johnson & Johnson will sich im Bereich der Neurowissenschaften verstärken und…

Pharmaindustrie: Johnson & Johnson übernimmt Intra-Cellular Therapies für 14,6 Milliarden Dollar

Die Übernahme gibt dem Johnson & Johnson Zugang zu einem in den Vereinigten Staaten stark nachgefragten Medikament. Damit stärkt der…

Johnson & Johnson mit Milliardenübernahme von Intra-Cellular - Intra-Cellular-Aktie +35 Prozent

Je Aktie legt J&J dafür 132 US-Dollar auf den Tisch und bezahlt damit insgesamt 14,6 Milliarden Dollar (14,2 Mrd Euro),…

ROUNDUP: Johnson & Johnson übernimmt Intra-Cellular für Milliardensumme

NEW BRUNSWICK/BEDMINSTER (dpa-AFX) - Der US-Pharma- und Medizintechnikkonzern Johnson & Johnson (J&J) stärkt sich mit dem Zukauf der Biopharma-Firma…

J&J to buy Intra-Cellular Therapies for $14.6 billion

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in…

2 Beaten-Down Dividend Stocks to Buy in 2025

Dividend stocks are great for various reasons, and its even better to invest in them while they are going through…

Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies

Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the…

Kreise: Johnson & Johnson in Gesprächen zu Intra-Cellular-Übernahme

NEW YORK (dpa-AFX) - Der US-Pharma- und Medizintechnikkonzern Johnson & Johnson (J&J) ist Kreisen zufolge an einer Übernahme der…

Johnson & Johnson in talks to acquire Intra-Cellular - Bloomberg

…

Johnson & Johnson Aktie: Schlüsselakteur im MedTech-Sektor

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Sanford C. Bernstein: Sanford C. Bernstein hat das Kursziel für die Aktie von…

Johnson & Johnson stock sinks on Varipulse concerns By Investing.com

Johnson & Johnson stock sinks on Varipulse concerns…

Johnson & Johnson: A Potential Beneficiary Of A Great Rotation

…

Johnson & Johnson: Im Saying Yes To This Mess

…

J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a…

J&J lung cancer treatment extends lives versus AstraZeneca drug

Johnson & Johnson (NYSE:JNJ) has said its chemotherapy-free combination extended lung cancer patients’ lives compared to AstraZeneca PLC (LSE:AZN)’s...…

Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson

Todays Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta Platforms, Inc. (META) and…

Oncology Pharmaceuticals Market Research 2024-2029, Profiles of Major Players - Bristol-Myers Squibb, Merck & Co, F. Hoffmann-La Roche, Johnson & Johnson, and AstraZeneca

This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough…

JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

Johnson & Johnson announces a global licensing deal with Kaken for the latters eczema candidate, KP-723, to further strengthen its…

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what…

Johnson & Johnson: Dividend Legend At A Discount

…

Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous…

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what…

[Latest] Global Dry Eye Syndrome Treatment Market Size/Share Worth USD 12,281.4 Million by 2033 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Johnson & Johnson Aktie: Citigroup senkt Kursziel - trotzdem ein Kauf?

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von der Citigroup: Aktuelle Bewertung Die US-Bank Citigroup hat das Kursziel für Johnson & Johnson…

Top Analyst Reports for Home Depot, Johnson & Johnson & Salesforce

Todays Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Johnson & Johnson…

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later

You dont have to be an income investor to like dividends. Many billionaires who definitely dont need income still have…

How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding

…

2 Very Healthy Dividend Stocks to Hold for Decades of Income

Checking a companys vital signs before investing in its stock for dividend income is essential. If the underlying company isnt…

Dr. Oz Held Millions In Healthcare Investments, Raising Potential Conflicts For Medicare And Medicaid

The celebrity doctor’s 2022 financial disclosure for his Senate run details holdings in stocks like UnitedHealth, CVS and Johnson &…

Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive

…

Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)

…

Johnson & Johnson: Tracking Well Above The Industry

…

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma

If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple…

dpa-AFX ProFeed